Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tonix Pharmaceuticals Holding (TNXP) Non-Current Debt (2023 - 2024)

Tonix Pharmaceuticals Holding has reported Non-Current Debt over the past 2 years, most recently at $4.7 million for Q4 2024.

  • Quarterly results put Non-Current Debt at $4.7 million for Q4 2024, down 28.87% from a year ago — trailing twelve months through Dec 2024 was $4.7 million (down 28.87% YoY), and the annual figure for FY2024 was $4.7 million, down 28.87%.
  • Non-Current Debt for Q4 2024 was $4.7 million at Tonix Pharmaceuticals Holding, down from $5.2 million in the prior quarter.
  • Over the last five years, Non-Current Debt for TNXP hit a ceiling of $6.6 million in Q4 2023 and a floor of $4.7 million in Q4 2024.